|Podcasts|March 30, 2011

Assessing the Risk of Violence: Ask the Professor

In the second in his series of podcasts, Dr Phillip Resnick answers questions psychiatrists often ask about assessing the risk of violence.

In the second in his series of podcasts, Dr Phillip Resnick answers questions psychiatrists often ask about assessing the risk of violence.

For Part 1 of this series, please go to Suicide Risk Assessment.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Signal in Noise: How Can Artificial Intelligence Benefit Psychiatric Practice?

ByJoseph F. Goldberg, MD,Roy Perlis, MD

June 30th 2026

Assessment of Suicide Risk in Individuals With Schizophrenia

ByCarla Kotzé, PhD, MMed, MPhil, FCPsych,Johannes Lodewikus Roos, MD, DSc, MMed, FCPsych

June 17th 2026

Podcast: Limitations of Current Diagnosis-Based Frameworks in Suicide Research. A Conversation With Jill Harkavy-Friedman, PhD, and Elizabeth Ballard, PhD

ByJenessa Johnston, PhD,Jill M. Harkavy-Friedman, PhD,Elizabeth Ballard, PhD

June 11th 2026

Understanding the Complexities of Suicide Risk: A Conversation With Jill Harkavy-Friedman, PhD, and Elizabeth Ballard, PhD

ByJenessa Johnston, PhD,Jill M. Harkavy-Friedman, PhD,Elizabeth Ballard, PhD

June 11th 2026

Suicide Risk Assessment in Patients Denying Suicidal Intent

ByIgor Galynker, MD, PhD,Jessica Walters

June 4th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Assessing the Risk of Violence: Ask the Professor

Related Content

Signal in Noise: How Can Artificial Intelligence Benefit Psychiatric Practice?

Assessment of Suicide Risk in Individuals With Schizophrenia

Podcast: Limitations of Current Diagnosis-Based Frameworks in Suicide Research. A Conversation With Jill Harkavy-Friedman, PhD, and Elizabeth Ballard, PhD

Understanding the Complexities of Suicide Risk: A Conversation With Jill Harkavy-Friedman, PhD, and Elizabeth Ballard, PhD

Suicide Risk Assessment in Patients Denying Suicidal Intent

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Vol 43, Issue 7 - Interactive

Beyond Deprescribing: A Formula for Excellent Clinical Care

AI Chatbots and the Erosion of Therapeutic Discomfort

Vagus Nerve Stimulation in Difficult-to-Treat Depression: When Does It Work Best?

Long-Acting Injectables in Schizophrenia: Closing the Gap Between Evidence and Practice